AIM/ BACKGROUND: Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. MATERIALS AND METHODS: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (>/=1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). RESULTS: At 3 months and at 1 year, group A patients showed decreased stool frequency (p < 0.01), stool consistency (p = 0.001), and number of incontinent episodes (p < 0.04). In contrast, stool frequency (p = 0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p < 0.05), anal sphincter pressures (p < 0.05) and ability to retain saline infusion (p < 0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects. CONCLUSION: Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.
AIM/ BACKGROUND:Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. MATERIALS AND METHODS: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (>/=1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). RESULTS: At 3 months and at 1 year, group A patients showed decreased stool frequency (p < 0.01), stool consistency (p = 0.001), and number of incontinent episodes (p < 0.04). In contrast, stool frequency (p = 0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p < 0.05), anal sphincter pressures (p < 0.05) and ability to retain saline infusion (p < 0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects. CONCLUSION:Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.
Authors: Adil E Bharucha; Alan R Zinsmeister; G Richard Locke; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton Journal: Gastroenterology Date: 2005-07 Impact factor: 22.682
Authors: Madhusudan Grover; Jan Busby-Whitehead; Mary H Palmer; Steve Heymen; Olafur S Palsson; Patricia S Goode; Marsha Turner; William E Whitehead Journal: J Am Geriatr Soc Date: 2010-05-07 Impact factor: 5.562
Authors: William E Whitehead; Satish S C Rao; Ann Lowry; Deborah Nagle; Madhulika Varma; Khalil N Bitar; Adil E Bharucha; Frank A Hamilton Journal: Am J Gastroenterol Date: 2014-10-21 Impact factor: 10.864
Authors: Alayne D Markland; Holly E Richter; Kathryn L Burgio; Thomas L Wheeler; David T Redden; Patricia S Goode Journal: Am J Obstet Gynecol Date: 2008-12 Impact factor: 8.661